Tracking the rise and fall of next-generation checkpoint targets for cancer
BioCentury’s analysis of next-generation checkpoint targets finds three that are gathering steam
As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead.
BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field turned to new targets that would extend efficacy beyond the subset of patients who respond to PD-1.
A longitudinal analysis of compounds targeting the most prominent next-generation T cell checkpoint proteins from 2015-19 shows LAG3, TIGIT and TIM3 pulling away from the pack, while therapies against the other targets have lagged, stalled or disappeared (see Figure: “Checking Up on Immune Checkpoints”).